A phase II study to determine the efficacy and safety of panitumumab in combination with chemoradiotherapy for unresectable or locally recurrent adenocarcinoma of the rectum with or without metastatic disease

Trial Profile

A phase II study to determine the efficacy and safety of panitumumab in combination with chemoradiotherapy for unresectable or locally recurrent adenocarcinoma of the rectum with or without metastatic disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2014

At a glance

  • Drugs Panitumumab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top